Results of Prospective Randomized, Open Label, Non -Inferiority Study of Tbo-Filgrastim (Granix®) Versus Filgrastim (Neupogen®) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non -Hodgkin Lymphoma.
Bhamidipati PK et al. Biol Blood Marrow Transplant. 2017 Aug 7. pii: S1083-8791(17)30619-5. doi: 10.1016/j.bbmt.2017.07.023. [Epub ahead of print].
Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome.
Kumar L et al. Bone Marrow Transplant. 2017 Aug 14. doi: 10.1038/bmt.2017.165. [Epub ahead of print].
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Holstein SA et al. Lancet Haematol. 2017 Aug 17. pii: S2352-3026(17)30140-0. doi: 10.1016/S2352-3026(17)30140-0. [Epub ahead of print].
Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-in Most.
Mikhael JR et al. J Clin Oncol. 2017 Aug 23:JCO2017747014. doi: 10.1200/JCO.2017.74.7014. [Epub ahead of print].
Retreatment and Prolonged Therapy with Subcutaneous Bortezomib in Patients with Relapsed Multiple Myeloma: A Randomized, Controlled, Phase III Study.
Terpos E et al. Eur J Haematol. 2017 Aug 12. doi: 10.1111/ejh.12937. [Epub ahead of print].
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Beck J et al. J Cancer Res Clin Oncol. 2017 Aug 21. doi: 10.1007/s00432-017-2504-5. [Epub ahead of print].